CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 140421-140719 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T15221","span":{"begin":0,"end":298},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Although prospective studies are needed to fully understand the effect of ADRB2 polymorphisms on response to therapy with a long-acting beta 2 -agonist, this analysis suggests that therapy with salmeterol and an ICS together is appropriate for Caucasian patients with differing Arg16/Gly genotypes."}

{"project":"Epistemic_Statements","denotations":[{"id":"T249","span":{"begin":0,"end":298},"obj":"Epistemic_statement"}],"text":"Although prospective studies are needed to fully understand the effect of ADRB2 polymorphisms on response to therapy with a long-acting beta 2 -agonist, this analysis suggests that therapy with salmeterol and an ICS together is appropriate for Caucasian patients with differing Arg16/Gly genotypes."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T370","span":{"begin":0,"end":298},"obj":"Sentence"}],"text":"Although prospective studies are needed to fully understand the effect of ADRB2 polymorphisms on response to therapy with a long-acting beta 2 -agonist, this analysis suggests that therapy with salmeterol and an ICS together is appropriate for Caucasian patients with differing Arg16/Gly genotypes."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1154","span":{"begin":212,"end":215},"obj":"Disease"}],"attributes":[{"id":"A1154","pred":"mondo_id","subj":"T1154","obj":"http://purl.obolibrary.org/obo/MONDO_0016575"}],"text":"Although prospective studies are needed to fully understand the effect of ADRB2 polymorphisms on response to therapy with a long-acting beta 2 -agonist, this analysis suggests that therapy with salmeterol and an ICS together is appropriate for Caucasian patients with differing Arg16/Gly genotypes."}